Abstract 12440: Utility of Urinary Excretion of β2 Microglobulin to Identify High Risk Subset for Restenosis in Patients Who Underwent Percutaneous Coronary Intervension
Background: Recent studies have shown increases in the urinary excretion of β2 microglobulin (β2MG) and N-acetyl-beta-D-glucosaminidase (NAG), which are considered to indicate the presence of tubulointerstitial damage in patients with chronic kidney disease (CKD). However, the changes in these urinary parameters during the clinical course of coronary artery disease (CAD) haven't yet been clarified. The aim of this study was to examine whether urinary β2MG and NAG levels are associated with increased restenosis rates in patients who underwent percutaneous coronary intervension (PCI).
Methods and Results: We studied consecutive 101 patients underwent PCI and who had repeated angiograms at a median of 6.9 months. Urinary β2MG, urinary NAG, microalbuminuria, estimated glomerular filtration rate (GFR), serum cystatin C, and high sensitive C reactive protein (hs-CRP) were measured at baseline and at follow up. Patients with restenosis had significantly higher urinary β2MG levels than those without (1.76 ± 0.69 vs 0.42 ± 0.11 μg/g; p < 0.01). Univariate regression analysis revealed that urinary β2MG (p < 0.01), hs-CRP (p < 0.01) were significantly related to restenosis. However, only urinary β2MG could predict restenosis (odds ratio 1.43; 95% confidence interval 1.031 – 1.996; p < 0.05) in multivariate regression analysis.
Conclusions: The urinary β2MG level is a strong independent predictor of restenosis in patients who underwent PCI.
- © 2010 by American Heart Association, Inc.